Published in Vaccine Weekly, November 15th, 2000
"A liposomal formulation of a 25-amino acid MUC1 lipopetide vaccine was tested in a Phase I study of 16 patients with either stage IIIB or IV NSCLC," stated Martin Clive Palmer and colleagues from the Cross Cancer Institute and Biomira, Inc., Edmonton, Canada.
Palmer et al. presented data from their study at the 36th Annual Meeting of the American Society of Clinical Oncology, held in New Orleans, Louisiana. The title of their presentation was "Phase I study of BLP25 (MUC1 peptide) liposomal vaccine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly